Ziltivekimab ZEUS trial results reveal that Novo Nordisk's IL-6 inhibitor successfully reduced inflammation markers in 6,300 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results